Pfizer To Appeal Lipitor Patents In Norway
The Norwegian Supreme Court has yet to decide whether it will hear the appeal.
The Borgarting Court of Appeal in Oslo ruled Tuesday that three patents covering the cholesterol-lowering drug would not be infringed by Ranbaxy's generic and that one other patent was invalid.
“We are disappointed by the court’s ruling,” said Allen Waxman, general counsel for the pharmaceutical giant. “But...
To view the full article, register now.